Keyword: ProQR Therapeutics
ProQR is licensing an RNA medicine from Ionis Pharmaceuticals for the treatment of retinitis pigmentosa, a form of rare, inherited blindness.
ProQR Therapeutics reported interim phase 1/2 data for its LCA10 treatment showing it improved vision for the majority of patients.
The offshoot starts life with seed funding and an RNA-based program targeting a rare genetic disease that causes strokes.
In our EuroBiotech roundup this week, Biopharma Credit completes $762 million IPO, BerGenBio prices NOK 400 million IPO, Merck inks Avillion deal and more.
ProQR Therapeutics saw its stock surge on the back of data from a small clinical trial of its cystic fibrosis drug QR-010.